In vitro trans-monolayer permeability calculations: often forgotten assumptions.

In designing effective therapeutic strategies, novel drugs must exhibit favorable pharmacokinetic properties. The physicochemical characteristics of a drug, such as pK(a), molecular weight, solubility and lipophilicity, will influence the way the drug partitions from the aqueous phase into membranes, and thus, will influence its ability to cross cellular barriers, such as the lining of the gastrointestinal tract and the blood-brain barrier. Physicochemical characteristics also influence the degree to which a drug is able to cross a barrier layer, and the route by which it does this; whether transcellular (across the cells)-by diffusion, carrier-mediated transport or transcytosis-or paracellular-by diffusing through the tight junctions between the cells. The in vitro model systems that are currently employed to screen the permeation characteristics of a drug often represent a compromise between high throughput with low predictive potential and low throughput with high predictive potential. Here, we will examine the way in which in vitro cellular permeability assays are often performed and the assumptions that are implied but sometimes forgotten, and we will make simple suggestions for improving the methodological techniques and mathematical equations used to determine drug permeability.

[1]  A. Walter,et al.  Monocarboxylic acid permeation through lipid bilayer membranes , 2005, The Journal of Membrane Biology.

[2]  D. Tosteson,et al.  Diffusion of Weak Acids across Lipid Bilayer Membranes: Effects of Chemical Reactions in the Unstirred Layers , 1973, Science.

[3]  Ronald T. Borchardt,et al.  Quantitative Approaches to Delineate Passive Transport Mechanisms in Cell Culture Monolayers , 1999 .

[4]  K. Luthman,et al.  Effect of molecular charge on intestinal epithelial drug transport: pH-dependent transport of cationic drugs. , 1999, The Journal of pharmacology and experimental therapeutics.

[5]  H Lennernäs,et al.  Human intestinal permeability. , 1998, Journal of pharmaceutical sciences.

[6]  P. Artursson,et al.  A method for the determination of cellular permeability coefficients and aqueous boundary layer thickness in monolayers of intestinal epithelial caco 2 cells grown in permeable filter chambers , 1991 .

[7]  Geri A. Sawada,et al.  Transcellular Permeability of Chlorpromazine Demonstrating the Roles of Protein Binding and Membrane Partitioning , 2004, Pharmaceutical Research.

[8]  M. Mayberg,et al.  A new dynamic in vitro model for the multidimensional study of astrocyte–endothelial cell interactions at the blood–brain barrier , 2002, Brain Research.

[9]  J Gutknecht,et al.  Diffusion of carbon dioxide through lipid bilayer membranes. Effects of carbonic anhydrase, bicarbonate, and unstirred layers , 1977, The Journal of general physiology.

[10]  S. Stavchansky,et al.  Estimation of the Relative Contribution of the Transcellular and Paracellular Pathway to the Transport of Passively Absorbed Drugs in the Caco-2 Cell Culture Model , 1997, Pharmaceutical Research.

[11]  M. Lucas,et al.  Intestinal surface acid microclimate in vitro and in vivo in the rat. , 1986, The Journal of laboratory and clinical medicine.

[12]  D. Begley,et al.  Lipids in blood-brain barrier models in vitro I: Thin-layer chromatography and high-performance liquid chromatography for the analysis of lipid classes and long-chain polyunsaturated fatty acids , 2002, In Vitro Cellular & Developmental Biology - Animal.

[13]  K Gubernator,et al.  Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. , 1998, Journal of medicinal chemistry.

[14]  J. Brillault,et al.  Prediction of Drug Transport Through the Blood-Brain Barrier in Vivo: A Comparison Between Two in Vitro Cell Models , 2002, Pharmaceutical Research.

[15]  Y F Shiau,et al.  Mechanisms maintaining a low-pH microclimate in the intestine. , 1985, The American journal of physiology.

[16]  Elizabeth M. Topp,et al.  Transport processes in pharmaceutical systems , 1999 .

[17]  D. Begley,et al.  Evaluation of the RBE4 Cell Line to Explore Carrier-mediated Drug Delivery to the CNS Via the L-system Amino Acid Transporter At the Blood-Brain Barrier , 2002, Journal of drug targeting.

[18]  G. Caldwell,et al.  In vitro permeability of eight beta-blockers through Caco-2 monolayers utilizing liquid chromatography/electrospray ionization mass spectrometry. , 1998, Journal of mass spectrometry : JMS.

[19]  A. Avdeef,et al.  PAMPA--a drug absorption in vitro model. 5. Unstirred water layer in iso-pH mapping assays and pKa(flux)--optimized design (pOD-PAMPA). , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[20]  Li Di,et al.  High throughput artificial membrane permeability assay for blood-brain barrier. , 2003, European journal of medicinal chemistry.

[21]  D. Begley,et al.  Lipids in blood-brain barrier models in vitro II: Influence of glial cells on lipid classes and lipid fatty acids , 2002, In Vitro Cellular & Developmental Biology - Animal.

[22]  M. Dehouck,et al.  Drug transport to the brain: comparison between in vitro and in vivo models of the blood-brain barrier , 1995 .

[23]  D. Scherman,et al.  High lipophilicity decreases drug transport across intestinal epithelial cells. , 1994, The Journal of pharmacology and experimental therapeutics.

[24]  Thomas J. Raub,et al.  Increased lipophilicity and subsequent cell partitioning decrease passive transcellular diffusion of novel, highly lipophilic antioxidants. , 1999, The Journal of pharmacology and experimental therapeutics.

[25]  Thomas J. Raub,et al.  Passive diffusion of weak organic electrolytes across Caco-2 cell monolayers: uncoupling the contributions of hydrodynamic, transcellular, and paracellular barriers. , 1995, Journal of pharmaceutical sciences.

[26]  D. Begley,et al.  The Blood‐brain Barrier: Principles for Targeting Peptides and Drugs to the Central Nervous System , 1996, The Journal of pharmacy and pharmacology.

[27]  M Gumbleton,et al.  Progress and limitations in the use of in vitro cell cultures to serve as a permeability screen for the blood-brain barrier. , 2001, Journal of pharmaceutical sciences.

[28]  C. Rice-Evans,et al.  Interaction between flavonoids and the blood–brain barrier: in vitro studies , 2003, Journal of neurochemistry.

[29]  W. Pardridge Peptide drug delivery to the brain , 1991 .

[30]  J. Tillement,et al.  Drug Transfer Across the Blood‐Brain Barrier: Correlation Between In Vitro and In Vivo Models , 1992 .

[31]  Alex Avdeef,et al.  Physicochemical Profiling (Solubility, Permeability and Charge State) , 2001 .

[32]  B. D. Anderson,et al.  In vitro models of the blood-brain barrier to polar permeants: comparison of transmonolayer flux measurements and cell uptake kinetics using cultured cerebral capillary endothelial cells. , 1999, Journal of pharmaceutical sciences.

[33]  Y. Sugiyama,et al.  Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[34]  A. Nomeir,et al.  Permeability of lipophilic compounds in drug discovery using in-vitro human absorption model, Caco-2. , 2001, International journal of pharmaceutics.

[35]  U Norinder,et al.  Experimental and computational screening models for the prediction of intestinal drug absorption. , 2001, Journal of medicinal chemistry.

[36]  M. Kataoka,et al.  Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.